• Page 14 Table 2 -Can the authors add a calculation for positive predictive value and negative predictive value for each statement in addition to specificity and sensitivity? Forgive my lack of understanding, but what exactly is the Chi square and p value a measure of here? What is being compared to what?
• Page 15 line 41 -what is the source of the patient information leaflets used to clarify those questions that confused subjects? What is the reading level of that information and was it created by an objective, reliable source? Or were these patient leaflets created by the pharmaceutical industry and subject to possible bias?
• Page 16 line 36 -when the authors say "beyond 6" do they mean higher than 6 or lower than 6?
Major Concerns
• My biggest concern is the authors' use of the term "drug-related problem". They do provide references for the source of this term which is helpful. But the term in North America appears to have a very different meaning. E.g. what the authors refer to as "technical DRPs" would simply be called prescribing errors in North America. The usual use of the term in North America would be a DRP (actually it would be called a drug therapy problem [DTP] in North America) is a problem that is either caused by a drug or requires a drug to correct. Fundamentally, I think the authors are off to a conceptually poor start for an international readership like BMJ Open.
• There is plentiful literature on screening tools for DRP/DTP's that the authors do not discuss or reference. In the interests of full disclosure, I am a co-author on some of it. • I'd like the authors to address in more detail what their tool is used for and how. By that, I mean that many of the instruments I discuss in the bullet point above seek to identify the DRP/DTP. These authors, on the other hand, seek to identify patients at risk for a DRP/DTP. That, in turn, requires a pharmacist to engage in a second action which is to identify if a DRP/DTP actually does exist. I'm having trouble identifying why a pharmacist should use the author's instrument and not an existing one that goes straight to identifying an existing or potential DRP/DTP.
• Page 25 Questionnaire -similar to what I have asked above. I would be very surprised if patients could dependably identify by name (especially only by generic name) the various anticoagulants and antidepressants listed in the questionnaire. In English the word "drainage" would not be used to describe a diuretic. How are patients to interpret "sleeping pill"? e.g. if a patient takes a benzodiazepine at bedtime for anxiety, is that an anxiolytic or a hypnotic and how is the patient to know the difference? The use of a binary "yes/no" response is concerning. Why is there not an "I don't know/Cannot remember" option?
• I would request a major revision and re-submission of the paper prior to making any recommendation regarding suitability for publication. I think my concerns above are fixable and would encourage the authors to make every attempt to do so.
REVIEWER
Fatemeh Saheb Sharif-Askari University Sains Malaysia, Malaysia, Penang REVIEW RETURNED 19-May-2017
GENERAL COMMENTS
The study entitled "Drug Associated Risk Tool -A new instrument to screen for patients at risk for drug-related problems", has developed drug associated risk tool (DART) by using patients self assessment questionnaire method. The authors claimed that the tool can be use to identify patients who are at increased risk of developing drugrelated problems. However, I think there're some points that require further clarification. Minor Concerns: 1. Page 3 line 18 -correct "fist" to read "first" Done 2. Page 9 line 16 -can the authors address issues related to social desirability bias when subjects provide comments to the authors on ease of use of the instrument A social desirability bias was possible when asking subjects directly about their opinion to our questionnaire. We were aware of this fact. Nevertheless, the major purpose of our study was to verify if the patients were able to give reliable answers to our questions. This was, what we verified by comparing their answers with objective data from their records. The five questions about the structure and content of the DART were of minor importance and we considered the effect of a possible social desirability bias as less important for our results. The question of whether subjects were able to recognize the structure of the questionnaire was answerable by looking at the questionnaire after the subjects had filled it in. I.e. Do the subjects set the crosses where they should set them? Do they realized that there was a second page? Had they filled in the whole questionnaire when they told us that they were finished? In most cases, the questionnaires were appropriately filled in. We added a comment on page 17: "We were aware of the possible existence of a social desirability bias when we directly asked patients for their opinion about the questionnaire."
3. Page 9 line 30 -did the authors offer any inducement or payment for subjects to participate in the study?
No, the authors offered no inducement or payment for subjects to participate. We inserted a comment on page 9 in the manuscript.
4. Pages 12 & 13 -I commend the authors for clarifying subjects' understanding of the questions in the instrument, but suspect that subjects still would not fully understand terms like "restricted kidney function" "kidney dysfunction" or "liver dysfunction". If this is a matter of how the original German is translated into English, please indicate as such. Most native speakers of English (unless highly educated and the authors do not provide the level of education of their subjects) would struggle to understand these terms.
This was for sure one of the biggest problems we were faced with. And therefore it was one of our main aim of this study, to examine, whether patients can understand and properly answer to such questions as you mentioned above. It is a matter of how the original German is translated into English, that the English expressions might sound strange to you. We directly translated the German expressions into English. Nevertheless, also the German expressions could be hard to understand for the subjects. For clarification we therefore used, as in the next-but-one question explained, the official patient information leaflets as source for these expressions. These leaflets are created by the manufacturer and are bound to the Swiss legal requirements concerning readability and understandability for patients. The information in these leaflets is required to be written in a way that patients can understand. Thank you for this valuable input. We added positive and negative predictive values. After detailed revision of our statistical calculation we completely agree with your suggestion to add the predictive values rather than the uncommon calculations of Chi square and p value.
Page 14
6. Page 15 line 41 -what is the source of the patient information leaflets used to clarify those questions that confused subjects? What is the reading level of that information and was it created by an objective, reliable source? Or were these patient leaflets created by the pharmaceutical industry and subject to possible bias?
We used the official patient information leaflets, contained in the packages of the medicines. They are created by the manufacturer and are bound to the Swiss legal requirements concerning readability and understandability. We added this information to the methods (see "revision of statements").
7. Page 16 line 36 -when the authors say "beyond 6" do they mean higher than 6 or lower than 6?
We meant a score lower than 6. We are sorry for this error and replaced the word "beyond" with "below".
Major Concerns 8. My biggest concern is the authors' use of the term "drug-related problem". They do provide references for the source of this term which is helpful. But the term in North America appears to have a very different meaning. E.g. what the authors refer to as "technical DRPs" would simply be called prescribing errors in North America. The usual use of the term in North America would be a DRP (actually it would be called a drug therapy problem [DTP] in North America) is a problem that is either caused by a drug or requires a drug to correct. Fundamentally, I think the authors are off to a conceptually poor start for an international readership like BMJ Open.
Thank you for this important input. We are aware of the fact that the terminology of DRPs and DTPs, respectively, varies by countries. As the BMJ Open is a European Journal, we tended to use the terminologies that are best known in Europe. Thank you for this comment. As you wrote yourself in your publication from 2012, the literature is replete with questionnaires and other tools that have been developed to identify DRPs/DTPs etc. We will add your self-assessment tool to our references. This is a very interesting project. It pursued an interesting approach by "recruiting" patients in these free seminars and offer them consulting. Most of the tools you referenced are focused on a very specific patient population e.g. patients with immunosuppressant, chemotherapy, herbal medicines, migraine and more. Or they focus on "only" adherence problems or medication cost. As they differ widely from our kind of questionnaire that focused on DRPs in general and was not limited to a special group of patients, we did not reference all of them. Our self-assessment tool is based on a previous project where we identified 27 risk factors for the development of DRPs. Risk factors from relevant literature were supplemented with results from qualitative research methods: We conducted a Nominal Group Technique with practitioners to ensure relevance in everyday practice and to identify risk factors possibly neglected in quantitative research methods. When we started with this project in 2011, as far as I know, this approach of combining literature and expert opinion was rather new. Clinical pharmacy in Switzerland is a rather new profession, we are struggling with limited resources and capacities. Already published screening tools, with a need to be filled in by the pharmacist would have been too time and personnel intensive to implement. As we lacked computerized patient files, we could not use already published electronic screening tools as well. A self-assessment tool that can be filled in by the patients themselves seemed to be a good solution to save resources and time. In addition, asking the patient directly can provide us important subjective information from the patient themselves, which we would not receive by just extracting data from electronic patient records. When we started with the development of the questionnaire, we did not see many self-assessment tools in the literature. The existing ones were based on other risk factors than those we identified. Therefore we decided to develop a new screening tool using the risk factors we identified in our previous project. Right from the beginning we were aware that some patients would have problems giving proper and complete answers to our questionnaire. Therefore this was the main aim of our study: to see if patients can give reliable answers to the questions in our self-assessment tool.
10. I'd like the authors to address in more detail what their tool is used for and how. By that, I mean that many of the instruments I discuss in the bullet point above seek to identify the DRP/DTP. These authors, on the other hand, seek to identify patients at risk for a DRP/DTP. That, in turn, requires a pharmacist to engage in a second action which is to identify if a DRP/DTP actually does exist. I'm having trouble identifying why a pharmacist should use the author's instrument and not an existing one that goes straight to identifying an existing or potential DRP/DTP.
While clinical pharmacy is well implemented in the USA, this specialized field of pharmacy is only in the beginning stages in most European countries. In Swiss hospitals, only very few clinical pharmacists participate on ward rounds in an interdisciplinary team of healthcare professionals in order to improve a patients' drug therapy. To meet the requirements of optimizing drug therapies while at the same time dealing with limited capacity, pharmacists are forced to target their clinical activities. A promising approach might be to focus on patients who are at the highest risk of experiencing DRPs. This was the reason why we started our research project. With a patient selfassessment tool, patients could fill in the questionnaire on their own when admitted to the hospital. There would be no need for the presence of a pharmacist in this first step. A nurse or a pharmacy technician could distribute the questionnaire to the patient. The patient fills in the questionnaire and is assigned a risk score. We did not yet develop the scoring system, as we first wanted to examine whether patients are able to give reliable answers to the questions, to see if a self-assessment is an appropriate way of screening. The clinical pharmacist then can focus on the high risk patients and visit them on the ward rounds.
11. Page 25 Questionnaire -similar to what I have asked above. I would be very surprised if patients could dependably identify by name (especially only by generic name) the various anticoagulants and antidepressants listed in the questionnaire. In English the word "drainage" would not be used to describe a diuretic. How are patients to interpret "sleeping pill"? e.g. if a patient takes a benzodiazepine at bedtime for anxiety, is that an anxiolytic or a hypnotic and how is the patient to know the difference? The use of a binary "yes/no" response is concerning. Why is there not an "I don't know/Cannot remember" option?
This is a valuable question. As mentioned above, we were aware of this problem. Patients might be unable to answer these questions. Therefore we conducted this study. We wanted to see, if patients can answer the questions in this self-assessment tool in a reliable way. We got mixed results. We discovered that patients could perfectly well identify some of their medicines but struggled with others.
We discussed these results on page 15 and 16 in our manuscript. "Drugs for drainage" is again an expression that was directly translated from German into English and therefore may sound unfamiliar to you. We do agree with your suggestion. We should have had included an "I don't know/cannot remember" option into our questionnaire. We did not skip this for purpose and we would consider it for future work.
Reviewer: 2 Reviewer Name: Fatemeh Saheb Sharif-Askari Institution and Country: University Sains Malaysia, Malaysia, Penang Please state any competing interests or state 'None declared': None declared 1. The reasons behind using qualitative method (patients self-assessment questionnaire) to validate DART; instead of using straight-forward quantitative method. Why not straight-forward the authors prepared an standard data collection forms to enter patient data. What is the reason behind this detour?
Thank you for your question. We did not use qualitative methods to validate our questionnaire. Patients had to fill in the DART (with predefined possibilities to answer like for example yes/no) and we compared their answers with data from medical charts. Either the patients answer was consistent with the information in the patient chart or not. This was a quantitative way to validate our questionnaire. We only used qualitative endpoints when we asked participants to give feedback concerning the feasibility and understandability of the questionnaire. I think your question was rather the question why we used a patient self-assessment tool instead of just extracting data out of an electronic patient chart? A self-assessment tool that can be filled in by the patients themselves seemed to be a good solution to save personnel, resources and time. In addition, asking the patient directly can provide us important subjective information from the patient themselves, which we would not receive by just pulling data out of electronic patient charts. Hopefully this clarifies things.
2. The reason behind choosing in-hospital patients instead of out-patient settings, which in my opinion, seems more suitable for application of qualitative validation method. I mean hospitalized patients they do have little opinion in selection of their medications, and it is solely the clinical pharmacist job to check for any drug-related problems by communicating with other health-care team.
However, patients in ambulatory setting have more highlighted role in discussing their medication options with both the prescribers and the clinical pharmacists. This is a reasonable question. We work as clinical pharmacists in the hospital. In most European countries, so in Switzerland, staffing restrictions are a major barrier for the development of clinical pharmacy services. At the same time, the need for clinical pharmacists is constantly rising. To deal with our limited capacities, we are forced to target our clinical pharmacy activities in the hospital to those patients who are most likely to benefit thereof. This was the reason why we wanted to develop a tool that enabled us to focus IN THE HOSPITAL on those patients who are at the highest risk of experiencing DRP's. If we were able to detect these "high risk patients" during their hospital stay, we could target our resources and discuss and solve the patient's therapy problems with the patient (and their physician) during the hospital stay. 
GENERAL COMMENTS
The authors have addressed all of my concerns to my satisfaction.
They may wish to make 2 small changes - Table 1 could include an expansion of what the abbreviations are (GRF etc). Table 2 -as I understand it, there were 31 interviewees from whom the data in Table 2 were collected. If so, how were there ≥ 150 answers for many of the assessment questions.
Overall, a well done paper. Nice work.
REVIEWER

Fatemeh Saheb Sharif Askari University Sains Malaysia, Malaysia
REVIEW RETURNED
25-Jul-2017
GENERAL COMMENTS
Thank you for submitting your revision. the revision is a significant improvement. I have no further comments.
VERSION 2 -AUTHOR RESPONSE
1. Table 1 could include an expansion of what the abbreviations are (GRF etc).
For better understanding I explained all abbreviations in the table 1. I corrected the term GRF (this was a typing error, I am sorry for this) into GFR (glomerular filtration rate), that I think is a very common term and, in relation with renal function, should be known by the readers.
2. Table 2 -as I understand it, there were 31 interviewees from whom the data in Table 2 were collected. If so, how were there ≥ 150 answers for many of the assessment questions.
You are right, this might be a little confusing when looking at the table. As we described in the text (Methods & Results: Revision of statements), after a first validation with 164 patients statements about heart insufficiency, renal impairment, and liver impairment showed low sensitivity due to possibly poor patient understanding. We rephrased these statements and revalidated them in 31
patients. For better understanding we added a footnote below the table 2.
All my marks for this second revision are colored in green, the old marks from the first revision are still colored in yellow.
